Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BTX 1801 for eradication of nasal Staphylococcus aureus carriage
ACTRN12620000456954Phase 2Completed
- Sponsor
- Botanix Pharmaceuticals
- Start
- Aug 2020
- Modality
- Small Molecules, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of BTX 1801 in Staphylococcus aureus infection and Staphylococcus aureus nasal carriage, sponsored by Botanix Pharmaceuticals. Primary endpoints: Safety and tolerability and Eradication of Staphylococcus aureus carriage at Day 12. Started Aug 2020; status: completed.
02
Drugs
BTX 1801
03
Conditions
Staphylococcus aureus infectionStaphylococcus aureus nasal carriage
Beyond the preview
Go deeper on ACTRN12620000456954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12620000456954.